Trial Profile
A Phase II Study With a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) - AMLSG 24-15
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Vosaroxin (Primary) ; Azacitidine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms AMLSG 24-15
- 27 Oct 2020 Status changed from discontinued to completed.
- 20 Dec 2019 Status changed from recruiting to discontinued.
- 19 Apr 2018 Status changed from not yet recruiting to recruiting.